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Abstract
Background: Malaria-endemic countries are switching antimalarial drug policy to artemisinin combination therapies
(ACTs) and the global community are considering the setting up of a global subsidy mechanism in order to make them
accessible and affordable. However, specific interventions may be needed to reach remote at-risk communities and to
ensure that they are used appropriately. This analysis documents the coverage with ACTs versus artemisinin
monotherapies, and the effectiveness of malaria outreach teams (MOTs) and Village Malaria Workers (VMWs) in
increasing access to appropriate diagnosis and treatment with ACTs in Cambodia, the first country to switch national
antimalarial drug policy to an ACT of artesunate and mefloquine (A+M) in 2000.
Methods: A cross-sectional survey was carried out in three different types of intervention area: with VMWs, MOTs and
no specific interventions. Individuals with a history of fever in the last three weeks were included in the study and
completed a questionnaire on their treatment seeking and drug usage behaviour. Blood was taken for a rapid diagnostic
test (RDT) and data on the household socio-economic status were also obtained.
Results: In areas without specific interventions, only 17% (42/251) of respondents received a biological diagnosis, 8%
(17/206) of respondents who received modern drug did so from a public health facility, and only 8% of them (17/210)
received A+M. Worryingly, 78% (102/131) of all artemisinin use in these areas was as a monotherapy. However, both
the VMW scheme and MOT scheme significantly increased the likelihood of being seen by a trained provider (Adjusted
Odds Ratios (AOR) of 148 and 4 respectively) and of receiving A+M (AORs of 2.7 and 7.7 respectively).
Conclusion: The coverage rates of appropriate diagnosis and treatment of malaria were disappointingly low and the use
of artemisinin monotherapy alarmingly high. This reflects the fragmented nature of Cambodia's health system in remote
areas and the reliance placed by these communities on informal vendors from whom artemisinin monotherapies are
widely available. However VMWs in particular are an effective means of improving access to malaria diagnosis and
treatment. The VMW scheme and the social marketing of RDTS and blister-packaged artesunate and mefloquine have
both been scaled up nationally. Case management in the public sector has also reportedly improved. Given recent
concerns regarding the development of artemisinin drug resistance on the Thai-Cambodia border, the effectiveness of
these measures in reducing the use of artemisinin monotherapy needs to be urgently re-evaluated.
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Background
Artemisinin combination therapies (ACTs) are now the
official drug of choice in most malaria-endemic countries.
Funds are being raised for the purchase of drugs through
a global subsidy mechanism, the Affordable Medicines
Facility-malaria (AMFm), with the recognition that they
must be heavily subsidized in order to make them afford-
able to those who most need them. Malaria control pro-
grammes now face the difficult task of implementation.
Whilst limiting as far as possible the inappropriate use by
those who do not have malaria, there is a need to ensure
that the drugs reach those who are most at-risk. This is par-
ticularly challenging because these are often poor com-
munities in remote areas, with no access to formal health
services. Depending on the local context, a number of dif-
ferent delivery mechanisms are possible including utilisa-
tion of the private sector and community-based strategies.
However there is little experience on which to base the
design of such programmes and few data to support tech-
nical and financial planning.
Cambodia provides such an experience. Although this
study was conducted a few years ago, the findings are all
the more relevant now in light of recent evidence that
resistance may be emerging to artemisinins in the region.
Cambodia was the first country to change policy nation-
wide to an artemisinin combination therapy of artesunate
and mefloquine in 2000 [1] and in doing so also spear-
headed some innovative strategies aimed at maximising
the chance of successful implementation. These included
specific community based interventions aimed to increase
access to accurate diagnosis and treatment. In order to
contribute to planning in other countries currently scaling
up provision of ACTs, this analysis documents the effect
of the policy change and initiatives at the level of the com-
munity in terms of coverage and adherence. The cost of
these interventions is described elsewhere [2].
Cambodia lies in the Mekong delta region bordering Thai-
land, Lao PDR and Vietnam. The population of approxi-
mately 13.6 million is mainly rural and predominantly
Khmer speaking. Following decades of turbulence and
social disruption it has recently entered a period of stabil-
ity and economic development.
However, malaria continues to be a major health problem
particularly in the thick tropical forests, the breeding
ground for the main malaria vectors, Anopheles minimus
and Anopheles dirus. These areas cover between 30–56% of
the land mass [3,4] and represent the most remote and
inaccessible areas in Cambodia. An estimated two million
people are at risk of malaria. One of the groups at highest
risk, with the worst access to health care, are recent
migrants from the relatively over-populated central
plains, who in recent years have moved into remote for-
ested areas that were previously dangerous and inaccessi-
ble because of conflicts, poor roads and unexploded
landmines. The other groups at-risk include ethnic minor-
ity families living in thickly forested villages in Mon-
dulkiri and Rattanakiri and a heterogenous group of
"temporary forest migrants" [5].
A recent cross-sectional survey revealed (smear positive)
prevalence rates of 3.0–12.3% [6]. Based on official statis-
tics, there were 71,258 confirmed cases of malaria of
which 63,739 (89%) were due to Plasmodium falciparum,
and 492 deaths in 2006 [7]. However, as the majority of
Cambodians do not seek treatment in public health facil-
ities, these numbers significantly underestimate the true
burden of disease especially in remote areas [6].
Malaria control continues to be a vertically controlled
programme run by the National Centre of Entomology,
Parasitology and Malaria Control (CNM) and currently
receives most of its funding from the Global Fund for
AIDS, TB and Malaria (GFATM).
In addition to the problem of the inaccessibility of the at-
risk population, a number of other factors make the con-
trol of malaria in Cambodia particularly challenging. Like
other malaria-endemic countries, most patients with fever
(80–90%) use informal health providers rather than pub-
lic health facilities [8-10]. These informal sector providers
range from village vendors, who sell everyday goods such
as cigarettes and simple drugs, to trained health workers
in larger towns. The latter are a heterogeneous group com-
posed of individuals who received training in the refugee
camps or from the Khmer Rouge as well as pharmacists,
nurses and doctors who are also officially employed in the
public sector [11]. Diagnosis is often presumptive leading
to the widespread inappropriate use of antimalarial drugs.
Treatment comprises small individual packets a contain-
ing a "cocktail" of three to five different tablets including
antipyretics, antibiotics, antimalarials, vitamins, antihis-
tamines and even steroids. The number of packets, and
therefore doses bought, varies according to a number of
factors including what the buyer can afford and the sever-
ity of illness. There is little government control of the
informal sector, which not only limits the impact of any
change in treatment policy and but also has resulted in the
widespread availability of sub-standard and fake drugs,
and in particular sophisticated imitations of artesunate
[12-14].
One of the major problems in Cambodia is multi-drug
resistance, particularly on the Thai-Cambodia border
[15,16]. Alarmingly, recent reports document decreasing
efficacy to ACTs which, if due to artemisinin drug resist-
ance, could have devastating consequences for global
malaria control [17,18]. There are a number of factors
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which may have contributed to this, but the way antima-
larial drugs have been deployed and used are probably
contributory, particularly if artemisinin monotherapy and
sub-standard drugs are prevalent.
When Cambodia changed its antimalarial drug policy to
artesunate and mefloquine (A+M) in 2000 it was hailed as
the first country to make a nationwide switch to an ACT
[19]. The policy change was accompanied by a number of
highly innovative strategies including:
&#x25AA; The local blister-packaging of the combination
into three age-group packages (ages six and above), to
encourage provider and patient adherence and to aid
product recognition and ensure consistent drug quality.
For children under the age of six years, 5 days of rectal
artesunate was the recommended treatment at the time
although this in currently being changed to oral A+M.
&#x25AA; The social marketing of blister-packaged artesu-
nate and mefloquine as "Malarine®" in the private sector
at a subsidized price.
&#x25AA; A publicity campaign to raise awareness about
fake antimalarial drugs.
&#x25AA; The promotion of the use of rapid diagnostic
tests (RDT), in both the public and private sector.
Malaria outreach and Village Malaria Workers
In addition to the change in national policy, there were a
few specific interventions aimed at increasing access to
diagnosis and treatment, namely a malaria outreach
project and the training of Village Malaria Workers
(VMWs). Both of these interventions and their costs are
described in more detail in a related paper [2].
The malaria outreach project was set-up and funded by
Médecins Sans Frontières (MSF) as part of their pro-
gramme of support in Anlong Veng district, Oddor
Meanchey province. The area in the northwest of Cambo-
dia is heavily forested and until 1999 had remained a
Khmer Rouge (KR) stronghold and therefore was largely
inaccessible. The collapse of KR power resulted in an
influx of non-immune migrants who came in search of
farmland and to collect forest products.
As a result one of the major health problems was an out-
break of malaria. Between May and August of 1999, in the
health centre alone, there were over 2000 confirmed
malaria cases, 400 hospitalizations and 18 deaths with
malaria accounting for one third of all outpatient and two
thirds of all inpatient cases [20]. At the time, the national
antimalarial guidelines for uncomplicated falciparum
malaria in that area was still single dose mefloquine, and
for complicated malaria, quinine and tetracycline. In
response to the outbreak and the known problem of
multidrug resistance, MSF switched first-line treatment to
an ACT of artesunate and mefloquine (A+M) and set up a
malaria control project. One of the core components were
malaria "outreach" teams (MOTs) which consisted of
teams of two people who went out daily from the health
centre to the settlements, in order to provide free diagno-
sis and treatment for malaria using RDTs and A+M. There
were initially two teams, expanding to four teams with the
aim of visiting each settlement once or twice per week
depending on population movement, road conditions
and information about suspected malaria outbreaks. The
population of the district at the time was estimated to be
19,029 in 64 settlements (Goubert L, personal communi-
cation). This figure is continuously changing as new settle-
ments appear and sometimes "older" ones disappear in
response to local and political problems and new devel-
opments.
The first experience of using VMWs in Cambodia came
from a European Commission (EC) funded community
based trial for insecticide treated bed nets (ITNs) in 30 vil-
lages in Rattanakiri in the Northeast of the country in
2001 [21]. This is a remote heavily forested area, sparsely
populated by ethnic minorities with low access to any
kind of health service. Malaria transmission is high with
cross-sectional parasite prevalence rates of between 5 and
57%. In order to address ethical concerns about having a
control group without any interventions, VMWs were
introduced in all villages. The VMWs were trained to per-
form RDTs on any villagers suspected of having malaria
and to provide treatment as per the national guidelines.
Diagnosis and treatment were provided free of charge and
the VMWs themselves received a minimal incentive of $4
per month. They were supervised and re-supplied
monthly by the provincial malaria staff. The resulting data
from this passive surveillance system exposed the scale of
the malaria problem and demonstrated that VMWs pro-
vided a practical means of access to diagnosis and treat-
ment. There was a further pilot project in the Khmer
speaking province of Koh Kong, after which the VMW pro-
gramme has been scaled up to cover 300 villages across
Cambodia [22] with support from the Global Fund.
This objective of this study is firstly to document the usage
of artemisinins and other antimalarials, following the
change in national policy and secondly to analyses the
impact of outreach clinics and VMWs in increasing access
to accurate diagnosis and treatment with ACTs.
Methods
Cross-sectional household surveys were carried out in
2002, in three different types of intervention areas: with
VMWs, outreach clinics and no specific interventions.
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Selection of the study villages was pragmatic in order to
include areas with interventions, and areas without inter-
ventions which had similar characteristics in terms of risk
of malaria; ecology; access to roads, health centres and
markets; and the socio-economic status of the communi-
ties in terms of livelihood, poverty and level of migration.
Thus the district of Anlong Veng, which was covered by
the outreach programme, was selected as were villages in
the Koh Kong VMW pilot project. The non-intervention
areas were in the neighbouring districts of Malai, Sampal-
ouen and Sotnikum and Thmar Bang (Figure 1). After
identifying all the villages covered by the health centre,
villages were excluded where no malaria cases had been
seen or reported and which were deemed too dangerous
(because of landmines or bandits). The remaining villages
were stratified into two groups according to accessibility.
Villages were then randomly selected from each stratum.
Selected villages were visited one or two days before the
day of the survey in order to inform and discuss the study
with the local community.
The survey
On the day of the survey, all households in the selected
villages were visited and, if an adult was present, screened
for inclusion. Where no adults were present, interviewers
were instructed to return to the house twice if possible,
before recording them as absent. The inclusion criteria
included anyone in the household who in the last three
weeks had either taken an antimalarial drug or who had
symptoms consistent with malaria. This was defined as
fever +/- headache +/- chills excluding other localizing
infection e.g. bloody or profuse watery diarrhoea, or
cough productive of coloured sputum as the predominant
symptom. The survey instrument consisted of a house-
hold module and an individual module which had been
developed and piloted following review of previous sur-
Map of study sites in CambodiaFigure 1
Map of study sites in Cambodia. The large yellow dots identify the areas studied in this study and the small red dots are the 
areas covered by the national drug usage survey carried out in 2002.
Anlong Veng
Sotnikum
Malai
Chik Phat
Thmar Bang 
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veys [10,23,24] and pre-survey qualitative work. The
household module contained questions on household
socio-economic status. The individual module was filled
out for each member of a household who fulfilled the
inclusion criteria and included sections on the most
recent and preceding episodes of fever. The questions
were designed to capture some key indicators of antima-
larial drug usage (Table 1). Respondents were also shown
a drug identification folder as a prompt to help them
recall the identity of drugs. Blood was taken by finger
prick for an RDT (Paracheck®) to estimate the proportion
of respondents who actually had P. falciparum malaria in
the previous two weeks. This relies on one of the usually
unwanted characteristics of tests based on Histidine Rich
Protein 2, (HRP2) which is that it persists in the majority
of treated cases for at least two weeks following effective
treatment [25]. Patients who were symptomatic and RDT
positive were treated as per national guidelines. An extra
200 μl of blood was also collected onto filter paper from
patients who had taken mefloquine and 30 "controls" in
order to measure drug levels and estimate the actual
amount of mefloquine taken by comparing with popula-
tion pharmacokinetic data. In the event, due to the small
numbers it was not feasible to carry out this part of the
study.
Ethical approval was granted by the Cambodian Ministry
of Health and the research ethics committees of the Lon-
don School of Hygiene and Tropical Medicine, and the
Oxford Tropical Medicine Network. Informed consent
was obtained from the community and individual partic-
ipants.
Data entry and analysis
Data were double-entered into EpiInfo 2000, cleaned and
analysed using STATA© (Version 8 and 9). The STATA sur-
vey commands were used to adjust for stratification by
intervention area and to adjust for clustering between
individuals in the same village. Observations were not
weighted as there was no sampling within villages. Differ-
ences in proportions were tested for significance using the
Pearson chi-squared statistic adjusted for the survey
design. Regression models were used for multivariate
analysis of variation in key outcomes using the STATA sur-
vey logistic (svy logistic) commands, which enable adjust-
ments to be made for clustering and stratification.
To simplify the analysis of the treatment types, drug treat-
ments were grouped into mutually exclusive categories
that were felt to be most informative and useful for com-
paring with recommendations. The groups were formed
hierarchically according to the presumed efficacy of the
drugs (artemisinins, quinine, chloroquine, then other).
For example the combination "quinine plus tetracycline"
was grouped as "quinine +/- other antimalarial".
As a proxy measure of adherence, the stated duration of
treatment was compared to the minimum recommended
duration because of the difficulty of determining with any
accuracy, the dose and timing of treatment. In addition,
the adequacy of treatment duration is particularly impor-
tant in determining cure and decreasing the likelihood of
resistance arising to the most efficacious and commonly
used antimalarials (artemisinins and quinine). For sim-
plicity, respondents who took drugs for longer than the
recommended duration were regarded as "adherent"
rather than creating an extra category for prolonged dura-
tion.
In order to compare the level of poverty between house-
holds, a poverty rank was established by performing a
principal component analysis (PCA) on the socio-eco-
nomic indicators collected in the survey. Such indices
have been accepted as reasonable proxies of socio-eco-
nomic status [26].
Results
Household characteristics
In all, 1491 households in 23 settlements in six adminis-
trative districts were visited (Table 2). Of note is the small
sample size from the VMW intervention area. This was
due to political problems that necessitated the withdrawal
of the survey from these villages early on in the study.
In total, 290 households were included in the analysis.
The population was very poor, even by Cambodian stand-
ards and many were recent arrivals with 57% of house-
holds having been in-situ for less than five years. A third
Table 1: Drug use indicators derived from questionnaire
Objective of malaria drug policy Indicator
Increase treatment from trained provider % of people with fever who went to a trained provider
Increase use of biological diagnosis % of people with fever who had a biological diagnosis
Reduce delay in treatment % of people who receive modern drugs within 48 hours of symptoms
Correct drug choice % of first-line drug (artesunate and mefloquine) as proportion of modern drugs
Decrease use of artemisinin monotherapy % of artemisinin monotherapy as a proportion of all artemisinin use
Adherence to ACT % of people who take artesunate and mefloquine for at least 3 days
Reduce patient costs Median drug cost of treatment
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had to borrow rice, or money for rice, in the last year.
Only 7% had access to water from a drilled well and one
quarter of households were completely landless. Housing
materials were of poor quality with 70% of roofs being
made only of leaves or bamboo. The majority of house-
holds did not own any draft animals (85%), any means of
transport (66%), or radio or television (64%). Level of
educational attainment was generally low, with 42% of
the adult respondents reporting having had no schooling
at all.
Individual characteristics
Altogether 361 (57% male) individuals fulfilled the inclu-
sion criteria: 251 from non-intervention areas, 88 from
MOT areas and 22 from VMW areas. The median age was
22 years, with 6% of the sample being five years or
younger. Age and sex distributions did not differ signifi-
cantly between different intervention areas. Of the sam-
ple, 70% (254) reported having only one episode of fever
in the previous two months, where an episode was
described as a period of fever separated from a previous
fever by more than three days. The remainder reported
having had two episodes except for two individuals who
had three episodes. For the most recent episode 12% (42/
361) did not receive any treatment, 56% (203/361)
received one treatment, 27% (99/361) received two treat-
ments and 5% (18/361) received three treatments.
Treatment with modern drugs
In non-intervention areas, modern drugs, meaning tablets
or pills as opposed to traditional remedies, were taken by
85% (213/251) of the respondents for the most recent
episode of fever. Surprisingly, the treatment rate was sig-
nificantly lower in the VMW area with only 14 out of the
22 (63%) respondents reporting to have received modern
drugs compared to 84% (74/88) in outreach areas (χ2 p =
0.054). By multivariate analysis the adjusted odds ratio
(AOR) of receiving modern drugs was 0.28 (95% confi-
Table 2: Summary description of sample
Total Intervention area
No intervention Outreach VMW
No. of districts included 6 4 1 1
No. of villages included 23 14 7 2
Total population of included villages 10,120 8,325 1,401 394
No. of households in included villages 2,093 1,767 252 74
No. of households visited 1,491 1,185 232 74
No. of households screened i.e. with adults present (% of those visited) 1,143 (77%) 884 (75%) 198 (85%) 61 (82%)
No. of households included (as % of those screened) 290 (25%) 208 (24%) 63 (32%) 19 (31%)
No. of individuals included 361 251 88 22
Mean age in years - 25.2 22.0 21.8
% male - 57% 58% 55%
Table 3: Outcomes (%, number and adjusted odds ratio (AOR)) for most recent episode of fever, by intervention area*
Outcome Intervention area
No intervention Outreach VMW
% (n) % (n) AOR (95% CI) % (n) AOR (95% CI)
Received biological diagnosis 17%
(42/251)
35%
(31/88)
2.4 (0.6–8.9)
(p = 0.102)
63%
(14/22)
10.7 (4.7–24.3)
(p =< 0.001)
Received modern drugs 85%
(213/251)
84%
(74/88)
0.7 (0.3–1.5)
(p = 0.340)
63%
(14/22)
0.28 (0.1–0.8)
(p = 0.03)
Received drugs from trained provider (of those who received 
modern drugs)
8%
(17/206**)
31%
(23/74)
4.0 (1.2–13.2)
(p = 0.023)
93%
(13/14)
147.5 (8.5–2571)
(p = 0.002)
Received artesunate and mefloquine (of those who received 
modern drugs)
8%
(17/210**)
22%
(16/74)
2.7 (1.0–7.6)
(p = 0.053)
64%
(9/14)
7.7 (1.8–28.2)
(p = 0.007)
Paid > $1 for treatment (of those who received modern drugs) 52%
(110/210**)
46%
(34/74)
1.2 (0.6–2.1)
(p = 0.525)
29%
(4/14)
0.55 (0.2–1.9)
(p = 0.107)
*Adjusted for sex, age (< 6 and 6–14 years), distance from health centre (> 2 hours by motorcycle), poverty rank (poorest 40% and richest 20%) 
and survey design. Results in bold highlight variables that significantly affect the AOR.
**Missing data therefore does not add up to 213
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dence interval (CI) 0.10 – 0.80) if the respondent was
from a VMW area, adjusting for age, sex, distance from
health centre, poverty and clustering in the survey design
(Table 3). Possible reasons for this are discussed later.
Timing of treatment
Overall, the median time to modern treatment from the
onset of symptoms was two days. "Delay in treatment"
was defined as time to treatment of more than two days.
In non-intervention areas, the delay in treatment was 37%
(107/289), compared to 25% (19/75) in outreach areas
and 57% (8/14) in VMW areas (χ2 p = 0.026). When
adjusted for clustering, this difference was no longer sig-
nificant (p = 0.1536). This suggests that clustering may
have contributed to the significance of the result and that
the sample may have been underpowered to detect the
difference between interventions. By multivariate analysis
the only factor to correlate with delay in treatment was age
five years or under, for whom there was less likelihood of
delay (AOR 0.58, 95% CI 0.35–0.98, p = 0.044).
Source of treatment
In non-intervention areas, the single most common
source (54%, 121/224) of initial treatment was a local vil-
lage vendor. This was followed by private health workers,
either at the providers' place (24%, 54/224), or at the
patient's home (6%, 12/224)). Village vendors were also
the most popular first source of treatment in areas with
MOTs (63%, 48/76), with only 17% (13/76) of respond-
ents first using the outreach service. However this was sig-
nificantly different in areas with VMWs, where 71% (12/
17) of respondents did first visit the VMW (Table 4).
Providers were grouped into trained (public, VMW, out-
reach) and "informal" (village vendors, private health
worker, other). In all, only 8% (17/206) of cases in non-
intervention areas who received modern drugs, received
them from a trained provider. This was much higher in
both outreach villages (31%, 23/74) and particularly
VMW villages (93%, 13/14) (p < 0.001) (Table 3). Chil-
dren under the age of 14 were three times more likely to
be taken to see a trained provider, but neither distance
from the nearest health centre, sex, or level of poverty
made any difference.
Diagnosis
Overall rates of biological diagnosis were very low. Only
17% of 251 individuals in non-intervention areas
reported having had a biological diagnosis for their most
recent episode of illness. This was significantly higher in
the areas with VMWs and outreach, at 63% (14/22) in the
former and 35% (31/88) (p = 0.009) in the latter (Table
3). By univariate analysis the odds ratio of having a test
were 8.5 (95% CI 3.3–21.4) if the respondent was from a
VMW area and 2.6 (95% CI 1.5–4.5) if they were from an
outreach area. Adjusting for the same factors as described
previously, the odds ratio of having a test was increased
11-fold in VMW areas and two-fold in outreach areas but
adjustment for clustering reduced the level of significance,
so that only the former reached significance (Table 3).
This reflects the variance between villages in non-inter-
vention areas with 2% of respondents from villages in
Chik Phat reporting having had a biological diagnosis
compared to 46% in Malai. Children aged six to 12 years
were three times more likely to have a test (95% CI 1.1–
7.8, p = 0.035), than other age groups. Sex, distance from
health centre and level of poverty did not have any effect.
The difference seen in intervention areas is mainly
explained by the fact that only 18% of the interactions
resulted in a biological diagnosis in the private sector, the
most popular source of treatment in non-intervention
areas. This compares to all consultations by VMWs and
outreach workers resulting in a biological test. The type of
test performed also varied significantly by intervention
area so that VMWs and outreach workers reportedly
always used RDTs. In contrast, only 15% (6/41) of tests at
private health facilities and 69% (11/16) of tests at public
health facilities were by RDT (Table 5).
The reported rate of positive tests was generally high, but
significantly lower if performed by RDT (67%) compared
to microscopy only (88%) (χ2 p = 0.009). This difference
is reflected in the decreased likelihood of having a positive
test if performed by a VMW (65%, 11/17) or an outreach
worker (75%, 3/4) compared to going to a private facility
or public health facility (Table 5). The relationship
between reported test results and treatment received is
explored below.
Type of antimalarial drugs
Respondents reported receiving altogether 464 treatments
in the previous two months. As explained, treatment usu-
ally consisted of little plastic bags containing a "cocktail"
mixture of different drugs. These contained a mean of 2.6
different tablets with 23% containing four or more tab-
lets. Of these treatments 63% (296) were known to con-
tain an antimalarial, 13% possibly contained an
antimalarial ("unknown") and 23% did not.
Within these treatments there were at least 28 different
combinations of antimalarials of which 15 contained an
artemisinin derivative. The type of treatment obtained
varied according to the provider. The most popular treat-
ments from village vendors contained no antimalarials
(30%, 56/188), chloroquine (26%, 49/188) or an artem-
isinin monotherapy (22%, 41/188), followed by treat-
ments containing quinine (12%, 22/188). For treatments
from private practitioners only 12% (11/95) contained
A+M, 34% (32/95) contained an artemisinin mono-
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therapy and 25% could not identified (24/95). The
remaining contained chloroquine (11%, 10/95) or qui-
nine (13%, 12/95). From public health facilities, 29% (8/
28) of treatments could not be identified and A+M and
quinine (with or without tetracycline) made up 14% (4/
28) each. Artesunate monotherapy and choloroquine
each accounted for 11% (3/28) of reported treatments.
From both VMWs and MOTs, three-quarters of treatments
received were identified as A+M (13/17 and 16/21 respec-
tively). The remainder being made up of no antimalarials
or unidentifiable treatments.
Comparison of the reported results of diagnostic tests
with the reported treatments received, suggest that VMWs
and MOT workers generally prescribed according to the
blood test results. Eleven out of seventeen (65%) respond-
ents who had RDT tests performed by VMWs, reported
positive results, all of whom received A+M. Two of six
respondents with negative tests also reported receiving
A+M. For respondents who had tests performed by MOTs,
16 out of 21 (76%) reported positive tests of whom 15
received A+M and one reported receiving no treatment.
Conversely, one of five respondents with a negative test
reported receiving A+M. Of the 16 respondents who had
diagnostic test in public health facilities, 13 (81%)
reported positive results of whom only three reported
receiving A+M. The other received quinine (3), chloro-
quine (3), other or unknown (4) and none (1). For tests
performed by private practitioners 89% (39/44) were
reported positive of whom only 5/39 (13%) reported
receiving A+M. This compares to 5/51 (10%) with no tests
and 1/5 (20%) for reportedly negative tests.
Analysis according to intervention area showed that in
non-intervention areas, the most commonly received mix-
tures were ones containing artesunate without mefloquine,
which accounted for 40% (102/257) of all treatments
containing antimalarials (Table 6). These treatments can
be effectively considered as artemisinin "monotherapy"
because even if they contained other antimalarial drugs,
the latter were generally either ineffective against P. falci-
parum malaria (e.g. chloroquine) or were taken for insuf-
ficient duration (e.g. quinine). In non-intervention areas
this accounted for 78% (102/131) of all artemisinin deriv-
ative use whereas in outreach and VMW areas this was
36% (10/28) and 7% (1/14) respectively.
In order to compare coverage with the first-line ACT,
artesunate and mefloquine, information on antimalarial
treatments taken for the most recent episode were com-
pared (Table 3). In non-intervention areas only 8% of
patients received artesunate and mefloquine compared to
22% and 64% in the outreach and VMW areas respectively
(p < 0.001). The adjusted odds ratio of receiving A+M was
2.7-fold higher in outreach areas and 7.7-fold higher in
VMW areas. No other factor was significantly associated
with a change in likelihood of receiving A+M.
Adherence
Most antimalarial drugs were taken for a median of two to
three days with a range of one to 14 days. As shown in
Table 7, adherence was better to the three-day regime of
A+M than to the three-day regime of chloroquine (77%
(34/44), versus 35% 22/63)). However when artesunate
was not taken as part of pre-packaged artesunate and
mefloquine, adherence was poor. If it was taken as part of
a cocktail of drugs containing another antimalarial, 13%
(4/31) of respondents reported taking it for the required 7
days. However if it was taken alone, without another anti-
malarial drug, adherence was higher at 28% (8/29),
reflecting the occasional practice where patients would
buy a blister-pack of 12 artesunate tablets rather than indi-
vidual packages of mixed drugs. Overall adherence to 7-
day treatment of an artemisinin without mefloquine was
20% (12/60). Adherence was even poorer with the less
palatable quinine-based regimes with none of those tak-
Table 4: First source of treatment by intervention area (n)
First source of treatment Intervention area %
None n = 317 Outreach n = 76 VMW n = 17
Village vendor 54% 63% 12%
Public health facility 6% 4% 0
Went to private practitioner 24% 7% 6%
Private practitioner came to home 6% 1% 0
VMW 1% 0 71%
Outreach 0.5% 17% 6%
Traditional healer1 3% 0 0
Other2 6% 8% 6%
1The number of "Traditional" treatments is probably underestimated. Patients often use local remedies early on in an illness, at the same time as 
modern medicines. These included local plants, rubbing with coins or cupping.
2"Other" included the military, de-mining organisations and forest rangers.
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ing quinine and tetracycline completing the recom-
mended seven days.
By intervention area, the likelihood of being adherent to
an antimalarial regime reflected the likelihood of receiv-
ing A+M so that in non-intervention areas adherence was
37% (80/218), in outreach areas 44% (34/78) and in
VMW areas was 90% (17/19). By univariate analysis the
odds (OR) of being adherent was 15-fold greater in VMW
areas (95% CI 3.3–65.1) but not significantly greater in
outreach areas. By multivariate analysis adherence was
not affected by age, sex, distance from closest public
health facility, schooling or level of poverty (data not
shown).
Community effectiveness
In order to estimate community effectiveness, the proba-
bility that a patient with malaria would receive an effec-
tive course of antimalarials was estimated from the
product of the probability of receiving an efficacious anti-
malarial, defined as either artesunate with mefloquine or
quinine, and the probability of being adherent. Adher-
ence was based on the behaviour of the aggregate sample
because of the small sample size and was taken as 77%
(34/44) for artesunate with mefloquine and 8% (3/37)
for quinine, with or without tetracycline. This resulted in
a community effectiveness of 9% in non-intervention
areas, 19% in outreach areas and 40% in the VMW area.
Rapid diagnostic test results of the study
Overall 355 study RDTs were performed at the time of
interview, of which 28% were positive. There was no sig-
nificant difference in positivity rate between intervention
areas and non-intervention areas. There was however con-
siderable heterogeneity within the non-intervention
group such that in Malai only one out of 44 people (2%)
tested positive compared to 40 out of 91 (44%) in Chik
Phat. There was no significant difference in the result if the
analysis was limited to the 215 who began treatment
recently (in the last three weeks) and who therefore might
have been expected to still be RDT positive had they been
parasitaemic before starting treatment. By multivariate
analysis (Table 8), in the model adjusted for study design,
the only factor significantly associated with an increased
likelihood of having a positive RDT on the day of the
study was being a child less than five years of age (AOR
2.5, CI 1.44 – 4.21, p < 0.001).
Cost to households of malaria
For each treatment sought, respondents were asked the
cost of consultation, diagnosis, drugs, transport (for the
patient and any companions), and "other" costs including
food. In the event, few respondents were able to report
disaggregated costs for consultation, diagnosis and there-
fore the costs are presented as reported drug costs, travel
costs and total costs are shown (Table 9). The median
direct costs to households for an episode of malaria was
$1.28 in a non-intervention with a maximum reported
cost of $55. This compared with a median cost of $0.90
(range 0–$33.70) in MOT areas and $0 (maximum $5.13)
in the VMW areas. This difference in cost between inter-
vention areas was mainly explained by the fact that the
cost of drugs from outreach teams and VMWs was either
very low or completely free, whereas drugs from village
vendors and private providers, the most popular sources
of treatment in non-intervention areas, cost a median of
$0.77 and $2.95 respectively (Table 10).
Cost to households of drugs
Overall, households spent a median of $0.77 for A+M
compared to $1.67 for treatments containing an artemisi-
nin derivative and another (non-mefloquine) antimalar-
ial, and $2.05 for treatments containing only an
artemisinin derivative. Treatments that did not contain
any antimalarial cost $0.38 and the most common non-
artemisinin antimalarial treatments cost a median of
$0.67 (for both chloroquine and/or tetracycline and qui-
nine without tetracycline) (Table 7). There was no differ-
ence between intervention areas in the likelihood of
paying more than $1 for treatment (Table 3). By multivar-
Table 5: Biological diagnosis, by type of provider
Type of provider No. of contacts (n = 
452)*
No. (%) of contacts 
resulting in biological 
diagnosis (A)
No. of RDTs (as % of A) No. of tests reported 
positive (as % of A)
Village vendor 232 3% (8) 38% (3) 50% (4)
Went to private 
practitioner
98 42% (40) 15% (6) 88% (36)
Public health facility 31 52% (16) 69% (11) 81% (13)
Private practitioner came 
to home
24 17% (4) 3% (1) 75% (3)
VMW 18 94% (17) 100% (17) 65% (11)
Outreach 23 96% (21) 100% (22) 77% (17)
Other 26 15% (4) 75% (3) 75% (3)
*Number of contacts is greater than number of individuals because some individuals had more than one contact
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iate analysis, only the level of poverty affected the likeli-
hood of paying more than $1 for drugs with those in the
poorest 40% being less likely than those in the middle
40% AOR 0.38, 95% CI 0.21–0.68).
Discussion
This study sought to document the impact of the change
in malaria treatment policy to artemisinin combination
treatments (ACTs) and the impact of different delivery
strategies in Cambodia, the first country to make a nation-
wide change in policy to ACTs. It differed from other treat-
ment seeking behaviour studies in also trying to estimate
the proportion of fever cases that were due to malaria
through the use of RDTs.
The main limitation of this survey is that the sample size
was relatively small. This was largely due to the difficulties
related to carrying out fieldwork in the remote jungle
areas where malaria occurs. Many communities were
located far from roads and were only accessible by foot or
canoe. The study was conducted in the rainy season, when
malaria is most prevalent but road conditions are at their
worst. In addition, in some areas there was a risk of unex-
ploded landmines which further limited access. The sam-
ple size from the VMW intervention area was particularly
small because for political reasons, the study had to be
withdrawn early from the area. The main consequence of
the small sample size is that some of the apparent differ-
ences between interventions and non-interventions areas
failed to reach statistical significance, after adjusting for
study design. However despite this limitation, significant
differences between interventions areas were still found.
Other limitations include the fact that this was an obser-
vational study undertaken after interventions had already
been implemented, and the sampling design which pur-
posively selected areas known to be malaria endemic
rather than a completely random selection. This was done
in order to limit the time and resources that would be
wasted in visiting villages with little malaria. However, as
discussed below, comparison with a survey conducted the
following year showed that the results were not dissimilar
[27].
As in other similar studies there were also potential biases
inherent in this kind of study. These include the inaccura-
cies in reported drug usage and results of diagnostic tests.
Recall bias with a tendency to recall positive rather than
negative test results may explain the surprisingly high
number of positive tests. To assist in validating the
responses, where possible, respondents' descriptions were
compared to available records and a drug identification
board was used. There was also a potential bias in exclud-
ing households in which an adult was not present at the
time of the study. In order to mitigate against this, com-
munities were forewarned of the day of the study and the
study itself was timed just after the planting season, when
village occupancy was close to a maximum.
Table 6: Type of antimalarial therapy received, by intervention area
Antimalarial therapy received (%) Intervention area % (n)
None n = 224 Outreach n = 78 VMW n = 21
Artesunate + mefloquine 11% (29) 23% (18) 52% (13)
Artemisinin derivative +/- other antimalarial 40% (102) 13% (10) 5% (1)
Quinine +/- other antimalarial 9% (22) 12% (9) 0
Chloroquine +/- other antimalarial 24% (62) 38% (30) 0
Unknown 16% (42) 14% (11) 33% (7)
P < 0.001
Table 7: Adherence and cost (in US$ (2005)) for most recent treatment
Regime (Recommended duration) % achieving recommended durations (n) Median cost in US$ (range)
Artesunate + Mefloquine (3 days) 77% (34/44) 0.77 (0 – 12.82)
Artemisinin derivative + other antimalarial (7 days) 13% (4/31) 1.67 (0.22 – 38.90)
Artemisinin alone* (7 days) 28% (8/29) 2.05 (0.38 – 26.70)
Quinine + tetracycline (+/- other antimalarial) (7 days) 0% (0/13) 1.11 (0.35 – 17.3)
Quinine (+/- other antimalarial) (7 days) 13% (3/24) 0.66 (0 – 11.10)
Chloroquine (+/- other antimalarial) (3 days) 35% (22/63) 0.67 (0.11–11.11)
Unknown - 3.59 (0 – 41.03)
* Based on studies of artesunate monotherapy [41-43].
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The first major finding in this study were that coverage of
ACTs was low and that there was widespread use of artem-
isinin monotherapy, constituting 78% of all artemisinin
containing treatments in non-intervention areas. The
other major finding was that significant improvements
could be made with specific interventions to improve
access to reliable diagnosis, and free drugs.
The findings of low ACT coverage in this study were later
confirmed in a larger national antimalarial drug usage sur-
vey the following year in nine districts in which 1277
household respondents in 36 villages participated. An
even higher proportion (92%) of treatments containing
an artemisinin derivative were taken without mefloquine
if they were not blister-packaged with mefloquine and
only 11% of adults and 2% of 116 children under five
years received treatment according to national guidelines
[27].
The main reason for the low coverage rate with A+M in
Cambodia was that most treatments were obtained in the
private sector and, as previously reported [28], treatment
in the private sector is often inappropriate. In the absence
of any interventions, only 8% of respondents sought treat-
ment from a public health facility for the most recent epi-
sode of a malaria-like illness, with the most popular first
source of treatment (56%) being untrained village provid-
ers. These findings are similar to rates found in other set-
tings with poorly functioning health systems [29-32] and
confirm previous reports in Cambodia. In other studies in
Ko Kong, only 2 to 4% [33,34] of patients first sought
treatment for malaria in the formal sector. In other areas
rates of 7 and 26% have been described [24,27].
These findings are particularly significant in view of recent
reports suggesting that artemisinin drug resistance may
have emerged in Cambodia. Since this study, case man-
agement in the public sector has improved with higher
rates of biological diagnosis and treatment with ACTs
[22]. In addition the VMW scheme and social marketing
blister-packaged artesunate and mefloquine (Malarine ®)
and RDTs have been scaled up. However, artemisinin
monotherapies continue to be available now despite the
World Health Organization ban [35] and action to further
limit their availability and use is urgently needed. Inter-
ventions are needed to improve the quality of service pro-
vided by private providers including through training [36-
38] and incentives, including the subsidy of appropriate
co-formulated ACTs. Urgent consideration should be
given to Cambodia as a priority country for the roll-out of
the AMFm. The findings in this study of low rates of diag-
nosis, high rates of usage for modern drugs (85%) and the
predominant use of "cocktail" mixtures of drugs suggests
that behaviour change communication needs to empha-
size diagnosis, and the purchase and use of complete
packages appropriate ACTs.
Clearly, priority should also be given to the delivery of
affordable good quality treatment through the public sec-
tor. The findings in this study suggest that VMWs in par-
ticular, appeared to be effective means of doing this. The
likelihood of receiving a biological diagnosis was
increased 11-fold and the likelihood of receiving A+M was
increased eight-fold. In addition, the use of artemisinin
derivative monotherapy was much lower than in non-
intervention areas. Surprisingly however, in the VMW area
a higher proportion of patients reported remaining
untreated despite having had malaria-like symptoms and
waited for longer before seeking treatment. This could be
for a number of reasons. The presence of a VMW in the vil-
lage may have allowed malaria patients to risk waiting for
longer to see how symptoms evolved before seeking treat-
ment especially if they had previous experience of not
receiving any treatment following a negative diagnosis.
Alternatively the delay may have been due a difficulty in
finding the VMW if they were in the field or elsewhere.
There may have also been personal reasons for the villag-
Table 8: Likelihood of positive study RDT**
Variable AOR (95% CI)* p
Outreach area 1.62 (0.88–3.01) 0.12
VMW area 1.06 (0.32–3.49) 0.92
Did not receive A+M in last 2 months 1.95 (0.97 – 3.91) 0.06
Did not receive any antimalarial received in last 2 months 1.04 (0.54–2.02) 0.90
Female 1.26 (0.77–2.07) 0.36
Child 6–14 years 2.46 (1.44–4.21) 0.00
Child < 6 years 0.64 (0.18–2.34) 0.50
Far (> 2 hours by motorcycle) 0.45 (0.26–0.79) 0.01
Poorest 40% 1.20 (0.67–2.15) 0.54
Richest 20% 1.14 (0.57–2.32) 0.71
Number of observations = 354
* Adjusted for study design. Results in bold highlight variables that significantly affect the AOR.
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ers not to consult the VMW although VMWs were selected
through a community consensus.
Coverage was lower than anticipated with the outreach
programme. One of the main reasons given by villagers
was that because the service was intermittent, they would
often end up seeking treatment from the private sector
rather than waiting for the next visit by the MOT.
Although coverage was lower than in villages with VMWs,
it must be stressed that the decision to implement MOTs
rather than VMWs because of the unique requirements of
the Anlong Veng setting. Much of the population had
arrived recently from disparate locations with little con-
nection between them and individual households were
struggling to survive, building themselves crude shelters
and clearing land. It was therefore felt that there was little
capacity or inclination for community volunteers. It may
also be that there was a difference in the philosophy of the
organizations involved which meant that different sys-
tems were favoured, with MSF being primarily an emer-
gency relief organization where medical treatment is
usually delivered by qualified providers, compared to the
EC-malaria project which was more concerned with find-
ing a means of increasing access that could be sustained
and applied elsewhere in Cambodia.
Reassuringly there appeared to be some recognition that
young children were particularly at risk of malaria, as they
were significantly more likely to receive modern treatment
within two days of symptoms and were three times more
likely to be seen by a trained provider sector and to receive
a biological diagnosis than older children and adults.
However, they were no more likely to receive the recom-
mended A+M than older age groups.
Data on drug costs suggested that households pay $0.5 to
$2.60 with a median of $0.77 for antimalarial drugs and
this was in fact the median costs paid for blister-packaged
A+M. The median cost of a course of treatment that con-
tained only an artemisinin drug on its own without
another antimalarial was $2.05 (range $0.90–2.69). Inter-
estingly this was more than treatments which contained
an artemisinin drug and also another non-mefloquine
drug such as chloroquine $1.67 (range $0.77–5.13). This
was because artesunate tablets, the most popular form of
artemisinin derivative, were generally sold either in whole
blister packets containing 12 artesunate tablets at a usual
cost of around $2 per packet, or as a single tablet packaged
within a "cocktail package" containing a number of other
cheaper drugs such as paracetemol and chloroquine to
constitute a single dose of treatment at a cost of about
$0.25–0.50 per packet. For the latter, the number of doses
of treatment bought would depend on a number of fac-
tors including how much the patient could afford and
how ill they were. The only variable with a significant cor-
relation to the amount of money paid for treatment was
poverty rank. This confirms previous findings of the rela-
tionship between poverty and treatment expenditure [39]
Table 10: Cost (US$) of drugs (for most recent treatment episode) by provider type
Provider n Median (Range) Mean (s.d.)
Village vendor 151 0.77 (0 – 12.82) 1.28 (1.86)
Went to private health worker 65 2.95 (0 – 41.03) 7.35 (9.56)
Public 17 0.95 (0 – 9.23) 2.41 (2.83)
Private health worker came to home 15 6.44 (0.44–15.38) 5.73 (4.23)
VMW 12 0 (0 – 1.78) 0.23 (0.54)
Outreach 18 0.64 (0 – 1.28) 0.51 (0.41)
Other 13 0 (0 – 1.54) 0.30 (0 – 0.57)
Total 291 0.77 (0 – 41.03) 2.79 (5.51)
Table 9: Costs for most recent treatment episode by intervention area
Intervention (n) Cost (US$)
Drugs Travel Total including other costs (e.g. food)
None (205) Mean (s.d.)* 3.24 (6.23) 0.38 (1.18) 4.31 (8.07)
Median (range) 0.88 (0 – 41.0) 0.00 (0–11.1) 1.28 (0 – 54.9)
Outreach (71) Mean (s.d.) 2.01 (3.22) 0.26 (0.89) 2.92 (5.32)
Median (range) 0.77 (0 – 17.9) 0.00 (0–6.41) 0.90 (0 – 33.7)
VMW (16) Mean (s.d.) 0.52 (1.28) 0.00 0.68 (1.37)
Median (range) 0.00 (0–5.13) 0.00 (0–0) 0.00 (0–5.13)
*s.d = standard deviation
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and adds weight to the argument that ACTs will need to
be provided either free or almost free if the biologically
vulnerable (who are usually the most economically vul-
nerable) are to be reached [40].
Reassuringly, the cost of treatment was less from trained
providers than from the informal sector. Treatment from
the VMWs was supposed to be provided free and the study
suggested that usually this was the case, although there
was evidence that small payments were made occasionally
(maximum $0.54). The median cost of treatment from an
outreach worker was reported to be $0.64 but ranged up
to $5.10. This is of concern as patients were supposed to
be charged only up to a maximum of $0.75 depending on
their means (as assessed informally by the outreach
worker) and it was said that the majority of patients
received their treatment for free. In contrast, treatment
from an informal village vendor cost a median of $0.77
and from a private health worker $2.95 if the patient went
to the health worker and $6.44 if the health worker came
to the patient's house.
Conclusion
This study has shown that a key challenge in changing
malaria treatment policy to ACTs is ensuring adequate
access to accurate diagnosis and ACTs in poor rural areas
where communities have limited access to any kind of
health care. Coverage was low in areas without specific
interventions to increase access and the use of artemisinin
monotherapy was alarmingly high. This is particularly sig-
nificant in view of recent reports of possible artemisinin
drug resistance arising on the Thai-Cambodia border [17].
Despite the small sample size, the study suggests that the
provision of free diagnosis and treatment through trained
VMWs is an effective means of increasing coverage in cer-
tain settings. Although the use of MOTs did not appear to
increase coverage as much as VMWs, they were deployed
in a very difficult area for malaria control with a fluid pop-
ulation of new migrants.
The Village Malaria Worker scheme and social marketing
of RDTS and blister-packaged artesunate and mefloquine
have been scaled up nationally. Case management in the
public sector has improved. Given recent concerns regard-
ing the development of artemisinin drug resistance on the
Thai-Cambodia border, the effectiveness of these meas-
ures in reducing the inappropriate use of artemisinin
monotherapy needs to be urgently re-evaluated.
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